CNTX-3001 (Centrexion Therapeutics)

CNTX-3001 is an investigational interleukin-13 (IL-13) inhibitor, specifically a monoclonal antibody, being developed by Centrexion Therapeutics for the treatment of chronic pain. While IL-13 is traditionally associated with Type 2 inflammation and allergic diseases, emerging research has implicated it in the modulation of pain signaling and neuro-inflammatory processes. By targeting and neutralizing IL-13, CNTX-3001 is intended to provide a novel, non-opioid approach to managing chronic pain conditions, potentially reducing the hypersensitivity associated with inflammatory and neuropathic states. The drug is part of Centrexion's broader strategy to develop targeted therapies that address the underlying biological mechanisms of pain hypersensitivity.